NOS3 and myocardial infarction: Preclinical studies have demonstrated the potential of transcriptional enhancers for eNOS in improving left ventricular remodelling and contractile dysfunction in rats with experimental MI [130], as well as in reducing hypertrophy/fibrosis and improving diastolic function in a rat model of diastolic heart failure [131].